Spirogen Ltd. announces a research collaboration and license agreement with Genentech for the discovery and development of antibody drug conjugates
London, UK, 6th January 2011

Spirogen Ltd. ("Spirogen") a leading oncology-focused company developing DNA sequence targeted agents, announced a multi-year research collaboration and license agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX:RHHBY).The two companies will collaborate on the discovery and development of antibody drug conjugates (ADCs) as potential anticancer agents, using Spirogen's proprietary PBD drugs and associate…
read more »